The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Bank OZK purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) in the second quarte

Artia Global Partners LP purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE: DG

SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader i

Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health

Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report)'s share price reached a new 52-week hig

SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader i

Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing sym

Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptom

Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but deb

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? W

Shares of Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report) have earned an average recomm

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou

BOSTON--(BUSINESS WIRE)--WHOOP, the human performance brand, today announced it is expanding access

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's

SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic

Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbr

Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help i

DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project cost

Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but

DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the

Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidan

U.S. stocks were down as Dow Jones fell 450 points on Thursday. Lockheed Martin (LMT) shares rose 11

Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript f

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar

Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.63-$10.83 to $11.05-$11.25 vs $

Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.

Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.12 per share which beat the analyst c

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the

Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announce

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the p

Quest Diagnostics (DGX) reported strong Q1 earnings, beating expectations and raising guidance. Anal

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and

Quest Diagnostics Q1 revenue grew 9.2% as organic volume surged. Discover how new partnerships and A

Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.45-$9.65 to $9.58-$9.78 vs $9.4

Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.50-$10.70 to $10.63-$10.83 vs $

Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $2.50 per share which beat the analyst c

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Li

New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data t